Zenith Capital (Zenith Capital) Treasury Stock : $0.00 Mil (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Zenith Capital's treasury stock for the quarter that ended in . 20 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Zenith Capital Treasury Stock Historical Data

The historical data trend for Zenith Capital's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Treasury Stock Chart

Zenith Capital Annual Data

Trend

Treasury Stock

Zenith Capital Quarterly Data

Treasury Stock

Zenith Capital Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines